Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a Targeted Approach for Immunotherapy Research
Hercules, CA — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
Messenger molecules such as cytokines are involved in the communication within the immune system and play a vital role in a variety of conditions including cancer and autoimmune diseases. Advancing discoveries in immunotherapy can be time consuming as existing immunoassay tools may not be tailored to cover specific targets including cytokine targets. The Bio-Plex Pro Human Immunotherapy Panel 20-plex covers biologically-researched cytokine targets that are associated with immunotherapy research.
About the Bio-Plex Pro Human Immunotherapy Panel 20-plex
The Bio-Plex Pro Human Immunotherapy Panel 20-plex is a ready-to-use, 1 x 96-well kit that contains premixed magnetic capture beads and detection antibodies, standards, and buffers that produce results for 20 different cytokines using only 12.5uL of sample. The Bio-Plex Panel maximizes laboratory efficiency by generating key actionable data in a single experiment. The kit is compatible with other Bio-Rad platforms including the Bio-Plex 200, Bio-Plex 3D Systems, as well as all other xMAP platforms.
For more information about the Bio-Plex Pro Human Immunotherapy Panel 20-plex and other Bio-Plex instruments, assays, and software, please visit www.bio-rad.com/bio-pleximmunotherapykit
Bio-Plex and Bio-Rad are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce new products, the opportunities that may result from such new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "offers," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.